Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Academisch Ziekenhuis Maastricht has 5 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a different examiner and a different art unit, with 5 examiners and 5 art units represented.
PAK, YONG D is the busiest examiner, with 1 pending matter. The one-matter-per-examiner pattern limits opportunities to reuse examiner-specific arguments, making claim strategy and disclosure support important on each individual case.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, YONG D | 1 | 74.7% | +14.2% |
| BOSQUES, EDELMIRA | 1 | 62.8% | +19.7% |
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
| SIMMONS, CHRIS E | 1 | 34.2% | +19.6% |
| PEEBLES, KATHERINE | 1 | 35.6% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 189d overdue |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 22d overdue |
| 18880021 | IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE | PAK, YONG D | — |
| 18722298 | Immunoprotective Type Implantable Cell Delivery Device | BOSQUES, EDELMIRA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 189d overdue |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 22d overdue |
| 18880021 | IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE | PAK, YONG D | — |
| 18722298 | Immunoprotective Type Implantable Cell Delivery Device | BOSQUES, EDELMIRA | — |
| 18576049 | MEANS AND METHODS FOR THE TREATMENT OF CALCIUM CRYSTAL DEPOSITION DISEASES | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 3772 | 1 |
| 1675 | 1 |
| 1622 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18880021 | IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE | PAK, YONG D | 1652 | §102§103§112 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18722298 | Immunoprotective Type Implantable Cell Delivery Device | BOSQUES, EDELMIRA | 3772 | §103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18576049 | MEANS AND METHODS FOR THE TREATMENT OF CALCIUM CRYSTAL DEPOSITION DISEASES | BORGEEST, CHRISTINA M | 1675 | §112 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 1622 | §103§112 | Final Rejection | 22d overdue | Pending | Aug 04, 2022 |
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 1617 | §102§103§112 | Non-Final OA | 189d overdue | Pending | Aug 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcademisch Ziekenhuis Maastricht has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Yong D Pak has the most, with 1 of Academisch Ziekenhuis Maastricht's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
